The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 8 23:10 ET

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8 03:48 ET

Jiangsu Recbio Technology Shareholders to Vote Dec. 24 on Share Issue

MT NewswiresDec 6 03:53 ET

Express News | Jiangsu Recbio Technology - to Issue Not More Than 143.1 Mln Domestic Shares at RMB5.59 per Share

ReutersNov 11 08:53 ET

Jiangsu Recbio Technology Initiates Phase III Clinical Trials for Shingles Vaccine

MT NewswiresOct 23 02:20 ET

RECBIO-B: 2024 Interim Report

HKEXSep 26 05:19 ET · Announcements